24.08.18: Not intended for U.S. and UK Media

Bayer secures approval in the EU for Xarelto® (rivaroxaban) for patients with coronary or peripheral artery diseaseXarelto is the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated in combination with acetylsalicylic acid (ASA) for the prevention of atherothrombotic events in patients with coronary artery disease or symptomatic peripheral artery disease at high risk for ischemic events / Launch first expected in Germanymehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news

Related Links:

More News: Peripheral Vascular Disease (PVD) | Pharmaceuticals | Vitamin K | Vitamins